Zydus

Zydus Lifesciences has received approval from the United States Food and Drug Administration to market select generic formulations in the U.S., strengthening its foothold in the world’s largest pharmaceutical market. The regulatory clearance underscores the company’s expanding pipeline and reinforces its strategy of leveraging complex generics to drive revenue growth. With pricing pressure intensifying in domestic markets, U.S. approvals remain critical for Indian drugmakers seeking higher-margin opportunities.

Zydus has introduced a new therapeutic offering, PEPAIR, aimed at addressing a range of respiratory conditions, reinforcing its focus on chronic and lifestyle-related diseases. The launch comes as respiratory ailments continue to rise due to urban pollution, changing lifestyles and post-infection complications. Industry experts view the move as strategically aligned with growing demand for targeted, patient-friendly treatments in pulmonary care.

Zydus Lifesciences has received approval from the US Food and Drug Administration for a drug used in the treatment of a blood disorder, marking a significant milestone in the company’s global pharmaceutical strategy. The regulatory clearance enhances Zydus’ presence in the highly regulated US market and reinforces its capabilities in complex and specialty therapies. The approval is expected to expand the company’s product portfolio while opening new revenue opportunities from regulated markets.

Zydus Lifesciences has received approval from the U.S. Food and Drug Administration (USFDA) to market Leuprolide Acetate Injection, a critical therapy used in the treatment of prostate cancer, endometriosis, and hormone-responsive conditions. The regulatory nod marks another milestone for the company as it strengthens its specialty and complex generics portfolio in the highly competitive U.S. pharmaceutical market. With this approval, Zydus aims to deepen its foothold in oncology and hormone-related therapeutics—segments that continue to see rising demand globally.

The United States Food and Drug Administration (USFDA) has directed Glenmark Pharmaceuticals, Granules India, and Zydus Lifesciences to recall certain pharmaceutical products from the US market due to quality and safety concerns. The recalls underscore the critical importance of regulatory compliance in global drug exports. While the specific products and batches vary by company, the action highlights challenges faced by Indian pharmaceutical firms operating in stringent overseas markets.

In a troubling turn for Indian pharmaceutical giants, Glenmark, Sun Pharma, and Zydus are facing product recalls in the United States due to regulatory non-compliance and manufacturing deficiencies. The U.S. Food and Drug Administration (USFDA) flagged multiple deviations from Current Good Manufacturing Practices (CGMP), leading to recalls of widely prescribed medications for cardiac conditions, neurological disorders, and mental health issues. These enforcement actions highlight rising regulatory vigilance in the U.S.